H-His(1-mtt)-OH

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: H-His(1-mtt)-OH
• 英文别名: (2S)-2-amino-3-[1-[(4-methylphenyl)-diphenylmethyl]imidazol-4-yl]propanoic acid
• 化学式: C₂₆H₂₅N₃O₂
• 分子量: 411.5
• InChiKey: USIYUUIKLMCEIP-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  85.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PEPTIDIC BB2 RECEPTOR AGONIST – SACCHARIDE FUNCTIONALISED CARBABORANE CONJUGATES<br/>[FR] CONJUGUÉS AGONISTE DU RÉCEPTEUR PEPTIDIQUE DE BB2 - CARBABORANE FONCTIONNALISÉ PAR UN SACCHARIDE
  申请人：UNIV LEIPZIG

  公开号：WO2019115611A1

  公开（公告）日：2019-06-20

  The present invention covers peptidic BB2 receptor agonist –saccharide functionalised carbaborane conjugate compounds of general formula (I), in which L-Gln, L-Trp, L-Ala, L-Val, β-Ala, L-His, L-Nle, Z, n, X, m, and CbDare as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment of cancer by means of boron neutron capture therapy.

  本发明涵盖了一类通用式(I)的肽类BB2受体激动剂-糖基化碳硼烷共轭化合物，其中L-Gln、L-Trp、L-Ala、L-Val、β-Ala、L-His、L-Nle、Z、n、X、m和CbDare如本文所述和定义，制备所述化合物的方法，用于制备所述化合物的中间体化合物，包含所述化合物的药物组合物和药物组合物，以及利用所述化合物制造用于通过硼中子俘获疗法治疗癌症的药物组合物的用途。
• [EN] SACCHARIDE FUNCTIONALISED CARBABORANE CONJUGATES OF HUMAN PEPTIDE Y<br/>[FR] CONJUGUÉS DE CARBABORANE FONCTIONNALISÉS PAR DES SACCHARIDES DU PEPTIDE Y HUMAIN
  申请人：UNIV LEIPZIG

  公开号：WO2019115609A1

  公开（公告）日：2019-06-20

  The present invention covers peptidic human Y1 receptor agonist - saccharide functionalised carbaborane conjugate compounds of general formula (I): X5PSX1PX6FPGX7X8X9PX10X11X12X13X2X14YYX3X15X16X17X4YINLITRPRY-NH2, in which F, G, I, L, N, P, R, S, T, Y, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, and X17 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment of cancer by means of boron neutron capture therapy.